229 related articles for article (PubMed ID: 18255056)
21. Psychoneuroendocrinological studies on chronic stress and depression.
Tafet GE; Smolovich J
Ann N Y Acad Sci; 2004 Dec; 1032():276-8. PubMed ID: 15677427
[TBL] [Abstract][Full Text] [Related]
22. Anxious-depressive comorbidity: effects on HPA axis and CNS noradrenergic functions.
Cameron OG
Essent Psychopharmacol; 2006; 7(1):24-34. PubMed ID: 16989290
[TBL] [Abstract][Full Text] [Related]
23. The serotonin-1A receptor in anxiety disorders.
Akimova E; Lanzenberger R; Kasper S
Biol Psychiatry; 2009 Oct; 66(7):627-35. PubMed ID: 19423077
[TBL] [Abstract][Full Text] [Related]
24. The stimuli-specific role of vasopressin in the hypothalamus-pituitary-adrenal axis response to stress.
Zelena D; Domokos A; Jain SK; Jankord R; Filaretova L
J Endocrinol; 2009 Aug; 202(2):263-78. PubMed ID: 19460853
[TBL] [Abstract][Full Text] [Related]
25. Differential patterns of HPA activity and reactivity in adult posttraumatic stress disorder and major depressive disorder.
Handwerger K
Harv Rev Psychiatry; 2009; 17(3):184-205. PubMed ID: 19499418
[TBL] [Abstract][Full Text] [Related]
26. Corticosteroid-serotonin interactions in the neurobiological mechanisms of stress-related disorders.
Lanfumey L; Mongeau R; Cohen-Salmon C; Hamon M
Neurosci Biobehav Rev; 2008 Aug; 32(6):1174-84. PubMed ID: 18534678
[TBL] [Abstract][Full Text] [Related]
27. Sex differences in depression and anxiety disorders: potential biological determinants.
Altemus M
Horm Behav; 2006 Nov; 50(4):534-8. PubMed ID: 16920114
[TBL] [Abstract][Full Text] [Related]
28. Salivary cortisol, serum lipids, and adiposity in patients with depressive and anxiety disorders.
Veen G; Giltay EJ; DeRijk RH; van Vliet IM; van Pelt J; Zitman FG
Metabolism; 2009 Jun; 58(6):821-7. PubMed ID: 19375126
[TBL] [Abstract][Full Text] [Related]
29. Pathogenic involvement of neuropeptides in anxiety and depression.
Alldredge B
Neuropeptides; 2010 Jun; 44(3):215-24. PubMed ID: 20096456
[TBL] [Abstract][Full Text] [Related]
30. Dissociative symptoms and neuroendocrine dysregulation in depression.
Bob P; Fedor-Freybergh P; Jasova D; Bizik G; Susta M; Pavlat J; Zima T; Benakova H; Raboch J
Med Sci Monit; 2008 Oct; 14(10):CR499-504. PubMed ID: 18830188
[TBL] [Abstract][Full Text] [Related]
31. Glucocorticoid receptor polymorphisms in major depression. Focus on glucocorticoid sensitivity and neurocognitive functioning.
Spijker AT; van Rossum EF
Ann N Y Acad Sci; 2009 Oct; 1179():199-215. PubMed ID: 19906241
[TBL] [Abstract][Full Text] [Related]
32. Current perspectives of the roles of the central norepinephrine system in anxiety and depression.
Goddard AW; Ball SG; Martinez J; Robinson MJ; Yang CR; Russell JM; Shekhar A
Depress Anxiety; 2010 Apr; 27(4):339-50. PubMed ID: 19960531
[TBL] [Abstract][Full Text] [Related]
33. Vasopressin antagonists as anxiolytics and antidepressants: recent developments.
Simon NG; Guillon C; Fabio K; Heindel ND; Lu SF; Miller M; Ferris CF; Brownstein MJ; Garripa C; Koppel GA
Recent Pat CNS Drug Discov; 2008 Jun; 3(2):77-93. PubMed ID: 18537767
[TBL] [Abstract][Full Text] [Related]
34. Effects of experimental panic on neuroimmunological functioning.
van Duinen MA; Schruers KR; Kenis GR; Wauters A; Delanghe J; Griez EJ; Maes MH
J Psychosom Res; 2008 Mar; 64(3):305-10. PubMed ID: 18291246
[TBL] [Abstract][Full Text] [Related]
35. Glucocorticoid receptor polymorphisms in major depression.
Claes S
Ann N Y Acad Sci; 2009 Oct; 1179():216-28. PubMed ID: 19906242
[TBL] [Abstract][Full Text] [Related]
36. The role of life events and HPA axis in anxiety disorders: a review.
Faravelli C; Lo Sauro C; Lelli L; Pietrini F; Lazzeretti L; Godini L; Benni L; Fioravanti G; Talamba GA; Castellini G; Ricca V
Curr Pharm Des; 2012; 18(35):5663-74. PubMed ID: 22632471
[TBL] [Abstract][Full Text] [Related]
37. Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists.
Holsboer F; Ising M
Eur J Pharmacol; 2008 Apr; 583(2-3):350-7. PubMed ID: 18272149
[TBL] [Abstract][Full Text] [Related]
38. Covariance between psychological and endocrine responses to pharmacological challenge and psychosocial stress: a question of timing.
Schlotz W; Kumsta R; Layes I; Entringer S; Jones A; Wüst S
Psychosom Med; 2008 Sep; 70(7):787-96. PubMed ID: 18725434
[TBL] [Abstract][Full Text] [Related]
39. Involvement and role of antidepressant drugs of the hypothalamic-pituitary-adrenal axis and glucocorticoid receptor function.
Nikisch G
Neuro Endocrinol Lett; 2009 Mar; 30(1):11-6. PubMed ID: 19300389
[TBL] [Abstract][Full Text] [Related]
40. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics.
Mathew SJ; Price RB; Charney DS
Am J Med Genet C Semin Med Genet; 2008 May; 148C(2):89-98. PubMed ID: 18412102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
